CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-13 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Sale | −3,822 | $28.01 | $107K | 239,727 |
| 2026-01-13 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Option exercise | +50,000 | $4.87 | $244K | 592,761 |
| 2026-01-13 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −49,800 | $27.60 | $1.4M | 542,961 |
| 2026-01-13 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −200 | $28.49 | $6K | 542,761 |
| 2026-01-13 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Option exercise · Stock Option (Right to Buy) | −50,000 | 100,000 | ||
| 2026-01-12 | Myles David C. CH. DISCOV. & NON-CLIN DEV OFF | Sale | −10,000 | $28.34 | $283K | 144,846 |
| 2025-12-26 | Bohen Sean President and CEO | Gift | −8,500 | 237,650 | ||
| 2025-12-23 | Zojwalla Naseem Chief Medical Officer | Option exercise | +50,000 | $7.02 | $351K | 103,997 |
| 2025-12-23 | Zojwalla Naseem Chief Medical Officer | Sale | −99,509 | $27.66 | $2.8M | 4,488 |
| 2025-12-23 | Zojwalla Naseem Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −50,000 | 156,818 | ||
| 2025-12-22 | Harmon Cyrus Director | Sale | −2,881 | $28.53 | $82K | 741,259 |
| 2025-12-22 | Zojwalla Naseem Chief Medical Officer | Option exercise | +42,818 | $15.25 | $653K | 146,815 |
| 2025-12-22 | Zojwalla Naseem Chief Medical Officer | Option exercise | +7,182 | $7.02 | $50K | 153,997 |
| 2025-12-22 | Zojwalla Naseem Chief Medical Officer | Sale | −100,000 | $28.04 | $2.8M | 53,997 |
| 2025-12-22 | Zojwalla Naseem Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −42,818 | 112,182 | ||
| 2025-12-22 | Zojwalla Naseem Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −7,182 | 206,818 | ||
| 2025-12-19 | Zojwalla Naseem Chief Medical Officer | Option exercise | +40,000 | $15.25 | $610K | 173,997 |
| 2025-12-19 | Zojwalla Naseem Chief Medical Officer | Sale | −57,079 | $28.03 | $1.6M | 116,918 |
| 2025-12-19 | Zojwalla Naseem Chief Medical Officer | Sale | −12,921 | $28.93 | $374K | 103,997 |
| 2025-12-19 | Zojwalla Naseem Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −40,000 | 155,000 |
Page 3 of 11 · 207 trades